Novavax is looking ahead to 2024, with the TGA currently assessing its submission for its updated monovalent XBB.1.5 COVID-19 vaccine and a plan to progress the development of its combination COVID-influenza vaccine.
Novavax looking to 2024 with monovalent COVID vaccine and potential combination
December 20, 2023 Latest NewsBioPharmaNews of the DayBioPharmaDispatch Executive
Latest Video
New Stories
-
Merck joins with Omico to improve access to cancer trials in Australia
May 22, 2025 - - Latest News -
New Zealand announces 12-month prescriptions in 2025 Budget
May 22, 2025 - - Latest News -
'I think we have to step up and help him to understand that he's got to deliver on it'
May 22, 2025 - - Latest News -
TGA approves first-of-a-kind medicine for early symptomatic Alzheimer’s disease
May 21, 2025 - - Latest News -
Examples are important as evidence of the problem, but be prepared to defend them
May 21, 2025 - - Latest News -
Trump administration invites companies to 'align' US pricing under MFN plan
May 21, 2025 - - Latest News -
NDIS minister restates the importance of 'nothing about us, without us!'
May 20, 2025 - - Latest News